Summary:
The drug maker Hetero has claimed that its consumption has led to quicker recovery of Covid-19 patients with mild symptoms than the standard treatment.
.
Pharmaceutical company Hetero has requested the Drug Controller General of India (DCGI) to approve the emergency use authorization of Molnupiravir drug in the country.
Molnupiravir is a tablet and can be given to mild patients.
Molnupiravir, a drug with antiviral properties, has been found effective in the treatment of corona patients in the third phase clinical trial.
The drug maker Hetero has claimed that its consumption has led to quicker recovery of Covid-19 patients with mild symptoms than the standard treatment.
Hetero entered into a license agreement with MSD, a company that manufactures and supplies Molnupiravir drug in India in April this year.
The said company supplies medicine to more than 100 countries of low and middle-income groups apart from India.
Interim results showed that fewer patients needed hospitalization in the group given Molnupiravir than those who received standard care during the 14-day follow-up.
Hetero is pleased to announce that the interim clinical results from Phase III Clinical Trials of Molnupiravir are optimistic.
Following these encouraging results, we have approached the DCGI, seeking emergency use authorization for the drug in India.
— Hetero (@heteroofficial) July 9, 2021
The company said, `Phase 3 Trial Demonstrates Statistically Significant fewer hospital admissions, faster time to clinical improvement and early negative SARS CoV-2 RT PCR with Molnupiravir Treatment in mild COVID-19 patients compared to standard of care alone.”
.